WallabyPhenox Announces First Patient Enrolled in PROMISE Study Evaluating Treatment of Medium Vessel Occlusion StrokeIRVINE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox today announced that the first patient has been enrolled in PROMISE (PROspective study on Management of Ischemic Stroke secondary to mEvo), an investigator initiated prospective study examining how medium vessel occlusion (MeVO) acute ischemic strokes are managed within the first 24 hours. The first subject was enrolled at Indiana University, Methodist Hospital. Dr. Devi Patra and Dr. Ann Jones are co-leads at Indiana University.
WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE TrialIRVINE, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox today announced the successful treatment of the first U.S. patient in the p48 and p64 MW HPC in Aneurysm Occlusion (PIANO) IDE trial, evaluating the p48 and p64 MW HPC Flow Modulation Devices for the treatment of intracranial aneurysms. The first two procedures were performed by Adel Malek, MD, PhD, Chief of Neurovascular Surgery at Tufts Medical Center in Boston, MA.
WallabyPhenox Restructures Debt and Accelerates Global GrowthIRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox, a global neurovascular medical technology company, today announced the successful completion of a significant financing round aimed at strengthening its financial foundation. The proceeds will be utilized to fully restructure the company’s capital framework and accelerate its long-term global growth initiatives.
